Explore the Therapeutic Effect of Theta Burst Stimulation on Emotion Regulation in Autism With Minimally Verbal Ability or Intellectual Disability

Launched by CHANG GUNG MEMORIAL HOSPITAL · May 14, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a special type of brain stimulation, called theta-burst stimulation, can help people with autism who have minimal verbal abilities or intellectual disabilities manage their emotions better. Researchers want to understand if this treatment can improve emotional regulation in individuals diagnosed with autism spectrum disorder (ASD). The trial is not yet recruiting participants, but it aims to include individuals aged between 8 and 30 years old, regardless of gender.

To be eligible for this study, participants must have a confirmed diagnosis of autism spectrum disorder and have minimal verbal ability or an intellectual disability, which means their IQ is below 70. However, certain individuals will not be able to participate. This includes those with serious neurological or systemic diseases, a history of severe brain injuries, implanted metal devices, or severe psychiatric disorders. If eligible, participants can expect to receive theta-burst stimulation treatment and will be carefully monitored throughout the trial to ensure their safety. This study could provide valuable insights into new ways to support emotional well-being in individuals with autism.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of autism spectrum disorder, confirmed by DSM-5.
• • Individuals with minimal verbal ability or intellectual disability (FSIQ \< 70).
• Exclusion Criteria:
• • Current or past severe neurological disorders, such as epilepsy, or significant visual or hearing impairments.
• • Current or past severe systemic diseases, such as cardiovascular disease, diabetes, or multiple sclerosis.
• • History of severe brain injury.
• • Presence of implanted metal devices, such as a pacemaker or medication pump.
• • Current or past severe psychiatric disorders, such as schizophrenia, bipolar disorder, or major depressive disorder.
• • Pregnancy.
• • Significant brain abnormalities, such as intracranial space-occupying lesions.
• • Family history of epilepsy.
• • History of febrile seizures.
• • Concurrent use of medications that increase the risk of seizures.
• • Sleep disorders during rTMS procedures.
• • Skin lesions or trauma at the stimulation site.
• • Deemed ineligible by the principal investigator (PI).
• • Participation in another clinical trial within the past month.
• • Suicidal ideation or suicide attempts within the past year.